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MaAortic dissection is the most devastating complication of thoracic aortic disease. In the more than 250 years since
thoracic aortic dissection was ﬁrst described, much has been learned about diseases of the thoracic aorta. In this review,
we describe normal thoracic aortic size; risk factors for dissection, including genetic and inﬂammatory conditions; the
underpinnings of genetic diseases associated with aneurysm and dissection, including Marfan syndrome and the role of
transforming growth factor beta signaling; data on the role for medical therapies in aneurysmal disease, including
beta-blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors; prophylactic surgery for
aneurysm; surgical techniques for the aortic root; and surgical and endovascular management of aneurysm and dissection
for different aortic segments. (J Am Coll Cardiol 2014;64:1725–39) © 2014 by the American College of Cardiology
Foundation.A ortic dissection is the most devastatingcomplication of thoracic aortic disease. Inpopulation-based studies, the annual inci-
dence ranged from 6 cases per 100,000 in a British
study (1), to 9.1 per 100,000 in women or 16.3 per
100,000 in men in a Swedish study that included
national healthcare registry diagnoses and autopsies
for all out-of-hospital deaths (2). The ﬁrst reported
case was King George II of Great Britain, who died
in 1760 of pericardial tamponade due to acute dissec-
tion of the ascending aorta, although the term “aortic
dissection” was not coined for another 40 years (3).
Since then, much has been learned about risk factors
for dissection, including aneurysmal disease and
genetic disorders, like Marfan syndrome, that in-
crease risk for both aneurysm and dissection. An
animal Marfan syndrome model and later studies
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gical therapies for aneurysm and dissection were
initially developed in the 1950s and have steadily
improved since then. More recently, endovascular
techniques and devices were developed to treat aneu-
rysms and dissections of the descending thoracic
aorta.
AORTIC SIZE, ANEURYSM, AND DISSECTION
AORTIC SIZE. Normal aortic diameter varies by age,
sex, and modality (4,5), increasing with age and body
surface area (Figure 1). At a given age, men typically
have larger aortas than women. Echocardiography,
computed tomography (CT) with contrast, and
cardiac magnetic resonance (CMR) with gadoli-
nium measure the internal diameter of the aorta,
whereas noncontrast CT and CMR generally measurel A. Wiener Cardiovascular Institute and Marie-Josée
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1726the external diameter. Thus, measurements
differ by the aortic wall thickness, usually 0.2
to 0.4 cm (4–8).
AORTIC ANEURYSM. An aneurysm is a per-
manent, localized arterial dilation to more
than 50% of the normal diameter. The histo-
pathology of some aortic aneurysms involves
medial degeneration (formerly called cystic
medial necrosis), characterized by elastic ﬁber
loss from the medial layer, loss of vascular
smooth muscle cells, and proteoglycan depo-
sition. Altered microribonucleic acid expres-
sion is implicated in increased activity of
matrix metalloproteinase (MMP)-2 and -9
(9,10), which lyse elastic ﬁbers and break
down the extracellular matrix. The media
within the aneurysm is also remodeled, with
smooth muscle cells oriented randomly,instead of in organized layers parallel to the aortic
lumen. Transforming growth factor (TGF)-b, a regula-
tory cytokine expressed by arterial wall vascular
smooth muscle cells, modulates MMP activity. In a
mouse aortic aneurysm model, disrupting TGF-b
signaling prevented aneurysm formation (11). There
are 2 TGF-b signaling pathways, and both play roles in
aneurysm formation (12,13). In the canonical pathway,
TGF-b binds at the cell surface to its type I or type II
receptors. The complex phosphorylates Smad2 or
Smad3, resulting in Smad4 recruitment and nuclear
translocation, and Smad-dependent gene transcrip-
tion. In the noncanonical pathway, TGF-b phosphor-
ylates extracellular signal-regulated kinase (ERK), Jun
N-terminal kinase, and p38. (Echo)
MR)
Proximal descending
thoracic aorta
F 1.9 cm, M 2.1 cm (CMR)
Mid descending thoracic aorta
F 2.5-2.6 cm, M 2.4-3.0 cm (CMR)
ortic Segments by Sex and Imaging Modality (6–8)
nce; Echo ¼ echocardiography; F ¼ female; M ¼ male.Medial degeneration may (at least initially) occur
as an adaptive response to wall stress in the aortic
dilation zone. Per Laplace’s law, wall tension (T)
equals pressure (P) multiplied by radius (R), or
T ¼ PR. Aneurysm formation increases wall tension,
causing further expansion of the aneurysmal seg-
ment. As the aorta enlarges, it loses distensibility.
When the tensile limit is reached, dissection may
occur, but aneurysms can occur without dissection,
and dissections can occur without aneurysms.
AORTIC DISSECTION. Dissection involves disruption
of the medial layer, with intramural hemorrhage
leading to propagation (especially when the intimal
layer is also disrupted) and tracking of blood within
the media. Two commonly used classiﬁcation
schemes are used for thoracic aortic dissection: the
DeBakey scheme categorizes dissections by the site of
origin; and the Stanford scheme categorizes dissec-
tions by involvement of the ascending aorta (Central
Illustration). In the DeBakey classiﬁcation, dissec-
tions originating in the ascending aorta are sub-
divided into those that propagate to the aortic arch
(type I) and those conﬁned to the ascending aorta
(type II), as opposed to those that originate in the
descending aorta (type III), regardless of whether
they propagate distally or retrograde. The Stanford
scheme is divided into type A dissections, which
involve the ascending aorta, and type B dissections,
which do not, regardless of point of origin (14).
RISK FACTORS FOR AORTIC DISSECTION
Clinical aortic dissection risk factors fall into 2 broad
categories: conditions that contribute to medial
degeneration and those that increase aortic wall stress.
Conditions associated with medial degeneration
include Marfan syndrome, Loeys-Dietz syndrome, the
vascular form of Ehlers-Danlos syndrome, inﬂamma-
tory diseases of the aorta, Turner syndrome, bicuspid
aortic valve, and familial thoracic aortic aneurysm and
dissection syndrome. The most common condition
that increases wall stress is hypertension, present in
more than two-thirds of patients with aortic dissec-
tion. Other conditions implicated in dissection are
likely mediated by hypertension, including pheo-
chromocytoma, cocaine use (15), and coarctation.
Physical trauma can increase wall stress and cause
dissection, as in weightlifting, deceleration injury in
motor vehicle accidents, or falls (16,17). Smoking also
increases dissection risk, likely by affecting TGF-b.
Prior cardiac surgery may increase the risk of dissec-
tion and complications. On the basis of International
Registry of Acute Aortic Dissection (IRAD) data, 15% of
patients with dissection had prior cardiac surgery (18),
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1727and black patients with an acute dissection were more
likely to present with a type B dissection, were
younger, were more likely to have hypertension and
prior cocaine use, and were less likely to have bicuspid
aortic valves or prior aortic cardiac surgery than white
patients (19).
GENETIC DISORDERS ASSOCIATED WITH MEDIAL
DEGENERATION. Marfan syndrome. Marfan syn-
drome results from mutations in the FBN-1 gene
encoding ﬁbrillin-1, a large glycoprotein deposited in
extracellular matrix microﬁbrils, including at the
periphery of elastic ﬁbers in the medial layer of
the ascending aorta. Fibrillin-1 regulates the cyto-
kine transforming growth factor-b type II receptor
(TGFbR2) (20). Normal ﬁbrillin-1 inhibits TGF-b; TGF-b
levels are elevated in Marfan patients, leading to
increased MMP activity and extracellular matrix
breakdown (21). In patients with a family history of
Marfan syndrome, the diagnosis can be made wheneither of 2 cardinal features is present: ectopia lentis or
aortic root aneurysm. Without a family history, both
cardinal features are required. Without these features,
diagnosis is based on the revised 2010 Ghent nosology,
which assigns points for common systemic correlates,
together with genetic testing for ﬁbrillin gene muta-
tions. Aortic aneurysm and dissection are the most
life-threateningMarfan syndromemanifestations (22).
Loeys-Dietz syndrome. Loeys-Dietz syndrome is
characterized by the triad of: arterial tortuosity and
aneurysms; orbital hypertelorism (widely-spaced
eyes); and biﬁd uvula or cleft palate. It results from
mutations in TGF-b receptors 1 or 2, and diagnosis is
conﬁrmed by genotyping. In the largest study of
Loeys-Dietz patients (n ¼ 90), 98% had aortic root
aneurysms. The mean age at death was 26 years
(range 0.5 to 47 years) due to thoracic aortic dissec-
tion (67%), abdominal aortic dissection (22%), and
intracerebral bleeding (7%) (23).
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The vascular form of Ehlers-Danlos syndrome is
characterized by: easy bruising; thin skin with visible
veins; characteristic facial features; and rupture of
arteries, the uterus, or intestines. Diagnosis requires
genetic testing to identify a defect in the COL3A1
gene, encoding type III collagen. The median survival
is 48 years, with most deaths due to dissection or
rupture of arteries in the thorax or abdomen, often
without aneurysms. Because these patients have such
fragile tissue, bleeding, wound dehiscence, poor
wound healing, ﬁstulae, and adhesions complicate
surgical repair of aortic dissections (24).
Bicusp id aort i c va lve . Bicuspid aortic valve is the
most common congenital abnormality affecting the
aorta, occurring in 1% to 2%of the population. Bicuspid
valves are classiﬁed by their anatomic appearance
(25). Type 0 or true bicuspid valves have no raphe and
2 equally-sized leaﬂets. More commonly, type I
bicuspid valves have a single raphe, usually between
the right and left coronary cusps. Less commonly, the
right and noncoronary cusps are fused. The raphe’s
position may create reproducible ﬂow patterns that
lead to aortic aneurysm development (26). Patients
with bicuspid valves are at increased risk for ascending
aortic aneurysm, dissection, and valvular aortic ste-
nosis and regurgitation (27,28).
Turner syndrome. Turner syndrome is characterized
by the absence of one X chromosome in a phenotypic
female (45X). Patients commonly have short stature
and ovarian failure. Less commonly, patients have
cardiac anomalies, including bicuspid aortic valve,
aortic coarctation, and aortic dilation, and these pa-
tients are at increased risk of dissection. Over 90% of
dissection cases in Turner syndrome had hyperten-
sion or structural disease (29,30).
Fami l ia l thorac ic aort i c aneurysm and dissect ion
syndrome. Between 11% and 19% of patients referred
for surgery with thoracic aortic aneurysm or dissec-
tion have ﬁrst-degree relatives with either aneurysm
or dissection, suggesting a familial syndrome without
speciﬁc identiﬁable genetic defects. Mutations were
identiﬁed in: TGFbR2, similar to Loeys-Dietz syn-
drome; smooth muscle cell–speciﬁc myosin heavy
chain 11, a protein involved in smooth muscle cell
contraction, where the dissections are associated
with patent ductus arteriosus; and ACTA2, encoding
smooth muscle-speciﬁc a-actin, also involved in
vascular smooth muscle cell contraction (4).
INFLAMMATORY CONDITIONS ASSOCIATED WITH
AORTIC ANEURYSM AND DISSECTION. Aortic medial
disease-associated vasculitides include Takayasu
arteritis, giant cell arteritis, and Behçet’s disease.Takayasu and giant cell arteritis are both T cell-
mediated panarteritides affecting the vasa vasora in
the adventitia and extending inward, with inﬂam-
mation resulting in either destruction, leading to
aneurysm formation, or ﬁbrosis, leading to stenosis.
Takayasu arteritis has Asian predominance and 10:1
sex predominance for women. Giant cell arteritis, or
temporal arteritis, predominantly affects females of
Northern European ancestry over age 50 years (31).
Behçet’s disease is characterized by oral mucosal ul-
cers and 2 of the following features: genital ulcers;
uveitis; retinal vasculitis; or skin lesions. Behçet’s
disease affects the aorta infrequently, but can be
associated with lymphocytic, histiocytic, eosino-
philic, and giant cell inﬁltration around the vasa
vasora, with media disruption leading to aneurysm
formation or aortic root necrosis (4).
MANAGEMENT OF AORTIC ANEURYSM
AND DISSECTION
The ﬁrst step in management of patients with aortic
aneurysm is risk factor control to slow the expansion
rate and reduce the risk of dissection or rupture.
Patients should be treated to control hypertension
to the lowest tolerated blood pressure, to optimize
lipids, and for smoking cessation, as smokers have
twice the aneurysm expansion rate of nonsmokers
and higher dissection rates (32). Patients should be
cautioned to avoid strenuous resistive (isometric)
exercise, such as heavy weightlifting, cocaine, and
other powerful stimulants, and to manage stress as
best they can. Life stressors can lead to acute hyper-
tension and abrupt wall pressure changes over time
(dp/dt), dramatically affecting aneurysm expansion
and increasing dissection risk. Patients with aortic
aneurysms who become pregnant require close
monitoring of aortic diameter and strict blood pres-
sure control.
MEDICAL TREATMENT WITH b-BLOCKERS. In the
1960s, using Tygon tubing as a model for aortic
dissection, Wheat et al. (33) showed that dissection
was initiated and propagated by hypertension and
pulsatile wall stress increasing dp/dt. b-blockers
decrease both (34), and this was proposed as the
mechanism by which propranolol decreased dissec-
tion in a turkey model of aortic aneurysms (35).
b-blockers may also prevent dissections by prevent-
ing the acute hypertensive response to emotional or
exertional events (16).
On the basis of ex vivo and animal data, b-adren-
ergic inhibition was studied in an open-label, ran-
domized trial of 70 Marfan patients: 32 were treated
with propranolol at a dose titrated to a heart rate
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1729below 100 beats/min during exercise or an increase in
systolic time interval of 30% (mean dose 212 mg); 38
patients in the control arm were untreated. Despite
greater aortic diameter in the propranolol arm at
baseline (34.6 cm vs. 30.2 cm), the mean slope of the
aortic ratio was 0.023 cm/year in the treatment group,
compared with 0.084 cm/year in the control group
(p < 0.001) (Figure 2) (36).
In a retrospective study of 155 children with Marfan
syndrome, despite greater dilation of the aorta at the
level of the sinuses of Valsalva (29.7 mm vs. 27.3 mm),
those who had taken a b-blocker (predominantly
atenolol, less frequently nadolol or propranolol) dis-
played a small but statistically signiﬁcant decrease
(0.16 mm/year; p < 0.05) in the aortic expansion rate
compared to untreated controls (37).
On the basis of these and other small studies,
b-blocker use for thoracic aortic aneurysms became
standard for Marfan patients and common in patients
with other forms of thoracic aortic aneurysms. How-
ever, a meta-analysis of 802 Marfan patients from
5 nonrandomized trials and 1 randomized trial
found no difference with b-blocker use in rates of
aortic dissection or rupture, cardiovascular surgery,
or death. Using a ﬁxed effects model, b-blockers
appeared to cause harm (38). There are also concerns
that b-blockers might decrease aortic elasticity and
regarding potential side effects during long-term
therapy in young people (5).
Seminal trials of b-blockers for thoracic aortic
aneurysm were limited to Marfan patients. Although
thoracic aneurysms arising in a variety of disease
states may exhibit medial degeneration, Marfan pa-
tients have greater aneurysm expansion dissection,
which occurs at smaller aortic diameters than in those100
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Reprinted with permission from Shores et al. (36).with other conditions, suggesting differences in
pathophysiology, tissue integrity, or disease severity
(39). Thoracic and abdominal aortic aneurysms are
also distinct histologically, with abdominal aneu-
rysms showing an inﬂammatory inﬁltrate, apoptosis
of vascular smooth muscle cells, extracellular matrix
fragmentation, and more frequent and extensive
atherosclerosis (40). Two randomized trials of pa-
tients with abdominal aortic aneurysms showed no
beneﬁts for b-blockers, and many tolerated treatment
poorly (41,42).
Although the role of b-blockers in preventing aortic
dissection has not been elucidated, once dissec-
tion has developed, they have a clearer role in man-
agement. Among 1,301 patients with acute aortic
dissection in the IRAD database (722 type A and 579
type B), b-blocker administration was associated with
improved survival, driven mainly by improvement in
those with type A dissections (43).
ANGIOTENSIN-II RECEPTOR BLOCKERS. Angiotensin-
II receptor blockers (ARBs) inhibit TGF-b through se-
lective angiotensin-II receptor AT1 blockade, with no
effect on AT2. Mice heterozygous for the Marfan
syndrome ﬁbrillin-1 C1039G mutation displayed
greater aortic expansion than wild-type mice. When
mice with the mutation were treated with proprano-
lol, they displayed slower aortic root expansion than
placebo-treated mice, but greater expansion than
wild-type mice, whereas treatment with losartan
resulted in the same aortic diameter, rate of aortic
root expansion, aortic wall thickness, and elastic ﬁber
architecture as wild-type mice, suggesting that los-
artan corrected the aortic morphology changes asso-
ciated with this Marfan syndrome model (11).
However, losartan’s beneﬁcial effect on aneurysm
growth requires intact AT2 signaling, and may be due
to indirect ERK inhibition (12).
Brooke et al. (44) reviewed the records of 18 pedi-
atric Marfan patients who had received ARB therapy
for over a year (17 losartan and 1 irbesartan) while also
taking b-blockers. Prior to ARB therapy, the mean
aortic root expansion rate was 3.54 mm/year; after
ARB therapy, the expansion rate slowed to 0.46 mm/
year (p < 0.001). There was no signiﬁcant blood
pressure reduction, suggesting another mechanism
for this effect (44). A prospective nonrandomized
study with 20 pediatric patients found that losartan
decreased aortic root size, and suggested that the
beneﬁt increased when therapy was started at an
earlier age (45). The recently published COMPARE
(COzaar in Marfan patients Reduces Aortic Enlarge-
ment) trial was a randomized, multicenter, open-label
study that enrolled 233 patients (of 330 planned) and
randomized 116 to losartan and 117 to no additional
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1730treatment. Most were taking b-blockers. Over 3 years
of follow-up, aortic root dilation was 0.77 mm in the
losartan group, compared with 1.35 mm in the control
group (p ¼ 0.014). The percentage of participants with
a stable aortic root over the 3-year study period was
50% in the losartan group and 31% in the control
group (p ¼ 0.022), with a number-needed-to-treat of
5.3 patients. The beneﬁt on aortic root size did not
appear related to the blood pressure reduction (46).
While intriguing, ARBs’ beneﬁts in Marfan
patients are not conclusive. Several trials to evaluate
losartan in patients with thoracic aneurysms are
underway, including the Pediatric Heart Network
study comparing the effects of atenolol and losartan
on aortic root growth over 3 years, which com-
pleted its planned enrollment (47,48), and the
Ghent Marfan Trial, which will evaluate losartan
versus placebo in 174 Marfan patients taking
b-blockers (49).
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS.
In a randomized, double-blind, placebo-controlled
trial of 17 Marfan patients who were taking
b-blockers, 24 weeks of perindopril resulted in
smaller aortic root diameters, and lower levels of
MMP-2 and TGF-b (50). Angiotensin-converting
enzyme (ACE) inhibitors block angiotensin I conver-
sion to angiotensin II upstream of the site of action of
ARBs, which selectively block the AT1 receptor but not
the AT2 receptor. In a mouse Marfan syndrome model,
at equivalent doses, the ACE inhibitor, enalapril, was
less effective at reducing aortic root growth than los-
artan (p < 0.0001). This may be due to a protective
effect of AT2 signaling on aneurysms in Marfan syn-
drome, speciﬁcally through AT2 receptor-mediated
ERK 1/2 inhibition. However, ACE inhibitors block
AT2 as well as AT1 signaling (12). The beneﬁt of ena-
lapril in the mouse model was comparable to that of
propranolol in an earlier study by the same group (11).
OTHER PHARMACOLOGICAL APPROACHES. In a
retrospective analysis of 649 patients with thoracic
aortic aneurysm, 147 patients taking statins were
compared to 502 who were not. After 3.6 years, fewer
patients taking statins reached the composite
endpoint of death, aortic rupture, dissection, or
repair, but aneurysm diameter was not affected (51).
In a retrospective analysis of 1,560 patients with
aortic aneurysms, the 369 (24%) taking statins had
lower rates of dissection rupture, death related to
surgery, or requirement for surgery for those with
aneurysms of the ascending aorta, aortic arch, and
descending aorta, but not for aneurysms of the aortic
root (52). In mice, doxycycline prevented aneurysm
formation through MMP-2 and MMP-9 inhibition;human studies suggested some beneﬁt for abdominal
aortic aneurysms, but the results are insufﬁcient to
support clinical recommendations for this line of
therapy (39,53,54).
SURVEILLANCE AND
PROPHYLACTIC SURGERY
Management of patients with aortic aneurysms in-
cludes surveillance of aortic diameter and, when it
reaches a critical point, referral for surgery. Regard-
less of aortic dimensions, symptomatic patients
should be referred for surgery. In asymptomatic
patients, the size of aneurysm is the main determi-
nant of the need for intervention.
Gott et al. (55) described 675 Marfan patients who
underwent aortic root replacement at 10 surgical
centers between 1968 and 1996. The 30-day post-
operative mortality was 1.5% for those undergoing
elective repair (n ¼ 455), 2.6% for urgent repair
(n ¼ 117), and 11.7% for emergent repair (n ¼ 103).
Compared to elective repair, the hazard ratio (HR)
for death with urgent repair was 3.33 (95% conﬁ-
dence interval [CI]: 1.14 to 9.79; p < 0.025) and for
death with emergent repair the HR was 7.40 (95%
CI: 2.84 to 19.30; p < 0.001). For 103 patients un-
dergoing emergent aortic root replacement within
24 h of surgical consultation, the indications were
acute dissection (n ¼ 73), chronic dissection (n ¼ 9),
chest pain, aneurysm diameter >7 cm, or New York
Heart Association functional class III or IV symp-
toms. Among 202 patients with acute or chronic
dissection, nearly one-half had aortic diameters
#6.5 cm. Thirty-day mortality after acute aortic
dissection was 9.1%. The authors concluded that
surgery should be undertaken electively when the
aortic root diameter is “well below” 6.5 cm to
reduce surgical mortality (55).
Elefteriades et al. (56–58) found that the risk of
rupture or dissection increased sharply with aortic
diameters >6 cm at the ascending aorta and >7 cm in
the descending aorta (Figure 3). At these dimensions,
the likelihood of aneurysm rupture or dissection was
31% for those with ascending aortic aneurysms and
43% for aneurysms of the descending aorta. Above
these critical dimensions, the risk of death associated
with surgery (2.5% ascending and 8% for descending
aortic aneurysms) was exceeded by the risk of com-
plications related to aortic rupture, dissection, or
death (14.1%) (Figure 4) (56–58).
Several professional societies, including the
American College of Cardiology (ACC), American
Heart Association (AHA), American Association for
Thoracic Surgery, and American College of Radiology,
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1731agree on a 5.5 cm threshold for surgical referral for
patients with dilated aortic roots, on the basis of the
relative risks of surgical complications, rupture,
dissection, and death (4,11). This cutoff will not
invariably avoid dissection at smaller diameters.
IRAD investigators found that the mean ascending
aortic diameter was 5.3 cm in 591 patients with type A
dissections between 1996 and 2005; 349 (59%) pa-
tients had diameters <5.5 cm. Independent predictors
of dissection at diameters <5.5 cm included history of
hypertension, radiating pain, and advanced age. The
overall 27% mortality rate was unrelated to aortic
diameter (59) (Table 1).
For a bicuspid aortic valve with dilated aortic root,
the 2014 ACC/AHA guidelines for valvular disease
recommend surgical referral when the aortic root is
5.5 cm or larger, similar to recommendations for pa-
tients without a bicuspid valve (Class I, Level of Evi-
dence: B). For a bicuspid valve with an additional risk
for dissection (family history or rapid growth), there
is a Class IIa recommendation for surgery when the
aortic root is 5.0 cm (Level of Evidence: C) (60). Pre-
vious valvular disease guidelines from 2008 and the
thoracic aorta guidelines used a cutoff of 5.0 cm, even
in the absence of an additional risk factor (4,61). Priorto release of the updated valvular disease guidelines,
there was considerable discussion about the appro-
priate cutoff for surgical referral for a bicuspid aortic
valve (27,62–64). In defending the new guidelines’
higher cutoff of 5.5 cm, the authors cite the low rates
of dissection with bicuspid valves, the paucity of data
regarding the degree of aortic dilation at which the
dissection risk substantively increases, and the
variability in aortic level (sinus of Valsalva vs.
ascending aorta) at which dilation occurs with
bicuspid valves (60).
Marfan patients should undergo echocardiography
at diagnosis to assess the aortic root and ascen-
ding aorta, then a follow-up echocardiogram after
6 months. If aortic root diameter is stable, patients
should have annual imaging until the diameter
reaches $4.5 cm or changes signiﬁcantly, when more
frequent imaging is advised (Class I, Level of Evi-
dence: C). Patients with Loeys-Dietz syndrome
should have complete aortic imaging at diagnosis
and after 6 months (Class I, Level of Evidence: C). If
stable, they should undergo yearly CMR from the
cerebrovascular circulation to the pelvis (Class I,
Level of Evidence: B). Patients with mutations that
predispose to aortic aneurysm formation and/or
dissection should have complete aortic imaging at
diagnosis and 6 months later (Class I, Level of Evi-
dence: C). Patients with Turner syndrome should
undergo imaging to exclude bicuspid aortic valve,
coarctation, or dilation of the ascending aorta. If
initial imaging is normal and there are no other risk
TABLE 1 Recommendations for Referral to Surgery by Disease and Aortic Root Diameter
Population
Aortic Root Diameter at Which Referral
for Surgery Is Recommended
General (4) $5.5 cm ascending aorta or growth >0.5 cm/yr
(Class I, Level of Evidence: C)
Marfan syndrome (4) $5.0 cm ascending aorta, unless family history of dissection
at <5.0 cm, or growth >0.5 cm/yr or
$4.0 cm and contemplating pregnancy (Class IIa, Level of
Evidence: C)
Loeys-Dietz syndrome (4) $4.2 cm by transesophageal echocardiogram (internal diameter) or
$4.4 to 4.6 cm by CT or CMR (external diameter)
(Class IIa, Level of Evidence: C)
Bicuspid aortic valve (4,60) Per 2014 ACC/AHA valvular disease guidelines:
>5.5 cm (Class I, Level of Evidence: B)
>5.0 cm with a risk factor for dissection (family history of
aortic dissection or growth >0.5 cm/yr) (Class IIa, Level of
Evidence: C)
>4.5 cm and undergoing surgery for symptomatic
severe aortic stenosis or regurgitation (Class IIa, Level of
Evidence: C)
Per 2010 ACC/AHA thoracic aortic disease guidelines:
$5.0 cm (Class I, Level of Evidence: C)
Plan for aortic valve repair or
replacement (4)
>4.5 cm (Class I, Level of Evidence: C)
ACC ¼ American College of Cardiology; AHA ¼ American Heart Association; CT ¼ computed tomography;
CMR ¼ cardiac magnetic resonance.
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1732factors for dissection, imaging should be repeated
every 5 to 10 years. If initial imaging is abnormal,
reimaging is indicated based on clinical deve-
lopments (Class I, Level of Evidence: C).
PREDICTING DISSECTION. Diseases of the thoracic
aorta may be clinically silent until dissection becomes
an emergency. Surveillance of high-risk populations
and prophylactic surgery decreased the frequency of
dissection, but these events are still too common and
catastrophic. Several biomarkers were investigated
for earlier detection of events that may precede aortic
dissection, including MMP and TGF-b levels (65).
Microribonucleic acid expression and MMP activity
measurements may elucidate distinctive proﬁles
associated with thoracic aorta diseases (9,10). For
dissection, these include C-reactive protein, calponin
(a troponin counterpart of smooth muscle), and
D-dimer, although these have not been studied pro-
spectively. In a meta-analysis of 11 studies that
included 349 patients, D-dimer had a pooled sensi-
tivity for dissection of 94% and speciﬁcity of 40% to
100%. These markers remain investigational, and
current guidelines do not recommend biomarker use
in routine clinical practice (4).
Sensitivity and speciﬁcity approach 100% for
diagnosis of aortic dissection by CT and CMR imaging,
but these ﬁgures presuppose clinical suspicion. To
improve diagnosis, the IRAD investigators formulated
a risk prediction tool that incorporates high-riskconditions (e.g., Marfan syndrome), certain features
of the presenting symptoms (abrupt onset of severe
or tearing quality pain), and clinical ﬁndings (shock,
new murmur of aortic regurgitation) into a score to
stratify patients into low-, intermediate-, or high-risk
groups (66).
SURGICAL MANAGEMENT FOR
TYPE A DISSECTION
Mortality associated with acute unoperated type A
aortic dissection has been estimated at 1%/h to 2%/h
during the ﬁrst 48 h. Hence, all patients with type A
dissection should be considered for urgent surgical
repair. In the IRAD database, in-hospital mortality for
patients managed surgically was 27%, compared with
56% for those managed medically (Figure 5) (67). For
those surviving to hospital discharge, 1-year survival
was 96% in the surgery group versus 89% in the
medical group, and was 91% after surgery versus 69%
at 3 years. In multivariable analysis, predictors of
long-term mortality were a history of atherosclerosis
(relative risk: 2.17; 95% CI: 1.08 to 4.37; p ¼ 0.03) and
previous cardiac surgery (relative risk: 2.54; 95% CI:
1.16 to 5.57; p ¼ 0.02) (68).
Uncertainty surrounds the appropriateness of sur-
gical management in certain populations, such as
those older than age 80 years, with neurological in-
juries, presenting late after the onset of dissection,
and with prior cardiac surgery. While 1 study sug-
gested that patients >80 years of age have poor out-
comes (69), another comparing patients younger or
older than 80 years of age found no difference in sur-
vival (70). In an analysis of 936 patients in IRAD,
one-third were over 70 years of age and 63 were
80 years of age or older; the rate of surgical repair
TABLE 2 Surgical Options for Ascending Aorta Repair
Surgical Procedure Description of the Procedure
Bentall (115–118) Total aortic root replacement with a composite valve
graft consisting of a Dacron aortic root and a prosthetic
aortic valve (either bioprosthetic or mechanical), with
reimplantation of the coronary arteries
Yacoub (root remodeling) (83) Dacron aortic root with a scalloped design
David (valve sparing) (82) Native aortic valve is reimplanted into a Dacron aortic graft
and coronary arteries are reattached
Ross procedure (119) Pulmonary valve autograft is placed in the aortic valve position,
and a homograft valve replaces the pulmonary valve
Aortic homograft (120) Consists of aortic valve and ascending aorta
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1733decreased with age, and surgical mortality increased
with age >70 years. There were not enough patients
>80 years of age to permit conclusions about a mor-
tality beneﬁt with surgery, and the authors recom-
mend considering surgery in all patients, regardless of
age (71).
In single-center reports, surgical repair for type A
dissection was performed in the setting of stroke,
without neurologic decline (72,73). Similarly, IRAD
analyses point to improved outcomes for surgical
management of patients who present with acute type
A dissection and stroke. In an analysis of 1,873
patients, 87 (4.7%) presented with stroke and 54
(2.9%) with coma. With stroke, mortality was 76%
with medical management and 27% with surgical
management (p < 0.001), and with coma, mortality
was 100% with medical management and 44% with
surgical management (p < 0.001). Logistic regression
analysis pointed to improved survival with surgery
after brain injury (odds ratio: 0.058; p <0.001). Five-
year survival rates for patients presenting with
stroke and coma were 23.8% and 0% with initial
medical management versus 67.1% and 57.1% with
surgery (log rank, p < 0.001), respectively (74). In
a later analysis of 2,202 IRAD patients with acute
type A dissection over a 16-year period, 132 (6%)
presented with stroke. These patients were older, had
higher rates of hypertension and atherosclerosis
compared to those who did not present with stroke,
were more likely to present with shock (13.8% vs. 7%;
p ¼ 0.005), and more likely to have aortic arch
vessel involvement (68% vs. 37%; p < 0.001), but less
likely to undergo surgical repair (73.5% vs. 85.4%;
p < 0.001). In-hospital mortality was 42.4% for pa-
tients with stroke, compared to 24.1% for patients
without stroke (p < 0.001). Among stroke patients,
5-year mortality was 100% for those managed medi-
cally and 22.1% for patients managed surgically (75).
In a single-institution study of 195 patients with
type A dissection, 93 (47%) presented more than 48 h
after the onset of symptoms. There was no difference
in long-term survival after 41.8 months among those
surviving the initial phase of management (76). It is
important to recognize the inherent selection bias
when analyzing those patients who survive the initial
48 h without surgical intervention (67,68).
Although some reports suggested that prior aortic
valve surgery might protect against complications of
type A dissection, speciﬁcally aortic regurgitation or
involvement of the right coronary artery in the
dissection, other reports implicated prior cardiac
surgery as increasing operative risk. Prior surgery
should not delay treatment of a type A dissection
(77,78).ROLE FOR SURGERY OR ENDOVASCULAR
REPAIR FOR ANEURYSM AND DISSECTION
The role for endovascular versus open repair differs on
the basis of the aortic segment containing the lesion.
Aneurysms or dissections of the ascending aorta are
treated surgically. There is a role for endovascular
repair in the descending thoracic aorta, with U.S. Food
and Drug Administration (FDA)–approved devices for
aneurysm and complicated dissection (79). Endovas-
cular approaches avoid the pain and recovery time
from thoracotomy and the risks of aortic clamping, but
their use may be limited in patients with inadequate
landing zones for stent placement, excessive aortic
dilation, inadequate vascular access, and severe aortic
atherosclerosis, which would increase the risk for
embolism. There are also considerablymore long-term
data for open repair (4).
1. ASCENDING AORTA ANEURYSM AND DISSECTION.
Open repair is the standard of care for patients
meeting the criteria outlined in Table 1. However,
there is controversy in the treatment approach to the
aortic root. Myriad options exist (Table 2), and
appropriate treatment centers on the normality of the
aortic sinuses. In older patients, the disease process is
usually effacement at the sinotubular junction. A
tube graft replacement above the sinuses, including
the proximal portion of the aortic arch, should be
used. These operations are reproducibly done, with
only modest hypothermia and low risk of death or
stroke (80).
In patients with proximal disease of the aortic root,
attention to aortic valve integrity is essential. The
modiﬁed Bentall procedure, where a composite valve
and graft is used to replace the entire aortic root, is
the standard of care for these patients. However,
many options for composite biological grafts now
exist, including a bioprosthetic valve sewn into a
Dacron graft, or use of the porcine xenograft Freestyle
(Medtronic, Freely, Minnesota) composite valve graft
(81). In the last decade, there has been intensive
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which allows treatment of the aortic root aneurysm
and reimplantation of the aortic valve in both
bicuspid and trileaﬂet valve patients (82). Another
valve-preserving option involves remodeling the
aortic root in order to recreate the sinuses of Valsalva
and sinotubular junction (83). Patients presenting
with type A dissection should be offered immediate
surgery. There is no role for medical stabilization
prior to surgery. Pre-operative coronary angiography
should not be performed routinely; this delays sur-
gical repair and increases the risk for aortic rupture
(84). Moreover, surgeons are unlikely to perform
coronary artery bypass grafting in the setting of a type
A dissection and the risk of wire misadventure in a
dissected aorta is not insigniﬁcant. The primary goal
of type A dissection surgery is not to entirely elimi-
nate the dissection, but to emerge with a live patient.
Only in DeBakey type II cases can the dissection be
completely eliminated. In most patients, there will be
persistent downstream dissection with patent false
lumen in the descending and abdominal aorta. The
ascending aorta is replaced from the sinotubular
junction to the undersurface of the aortic arch. If the
aortic root is involved, the operation may be
extended proximally to address pathologic or aneu-
rysmal aortic sinuses. There is little role to expand
the operation to include full transverse arch replace-
ment, as this increases operative risk without elimi-
nating all diseased tissue.
There is no role for endovascular repair of
ascending aortic aneurysms or type A dissections
(85,86).
2. AORTIC ARCH ANEURYSM AND DISSECTION. The
aortic arch was the last aortic section to be success-
fully replaced surgically, due to the difﬁculty of
maintaining perfusion of the head, neck, and upper
extremities. From the 1950s through 1970s, high
mortality and neurologic morbidity rates with surgi-
cal arch replacement improved with the introduction
of deep hypothermic circulatory arrest (87) followed
by advances in intraoperative cerebral perfusion
(88,89). In a retrospective analysis of 347 patients
who underwent surgical aortic arch replacement from
1993 to 2007, 95 underwent total arch replacement
with hypothermia and circulatory arrest. For those
who also received selective antegrade cerebral
perfusion, mortality was 6% compared to 34.6% for
those who did not, and stroke occurred in 6% versus
19.2%. Elective cases were even safer, with a mortal-
ity rate of 2.7% and strokes in 5.4% (89).
Current guidelines provide Class IIa recommenda-
tion for open surgical repair of the aortic arch. Forproximal arch disease, partial arch replacement and
ascending aorta repair are recommended. Total arch
replacement is reasonable for acute dissection when
the arch is aneurysmal or there is extensive destruc-
tion; for aneurysms that involve the entire arch; for
chronic dissection with arch enlargement; and for
distal arch aneurysms that involve the proximal
descending thoracic aorta. Repair is also recom-
mended for arch diameter >5.5 cm in asymptomatic,
low-risk patients with isolated degenerative or
atherosclerotic aneurysms (4).
Although endovascular stent grafts are not FDA-
approved for arch aneurysms, and randomized data
are lacking, endovascular or hybrid procedures
(combined endovascular and vascular surgery pro-
cedures) are increasingly used for patients at high
surgical risk due to age or medical comorbidities.
One type of hybrid procedure involves extra-
anatomic bypass, either carotid-carotid or carotid-
subclavian, to permit a stent graft to cover the
origin of the carotid artery (90). Hybrid procedures
for the aortic arch also include “debranching” pro-
cedures, where affected arch vessels are sequentially
surgically anastomosed to a Dacron graft, effectively
removing the branches from the aortic arch (91).
Because of high morbidity and mortality, these pro-
cedures are reserved for patients at high surgical
risk.
3. DESCENDING THORACIC AORTA ANEURYSM AND
DISSECTION. The descending thoracic aorta extends
from after the arch to proximal to the celiac axis. For
saccular aneurysms or degenerative or traumatic an-
eurysms of the descending thoracic aorta exceeding
5.5 cm, endovascular stent-grafting should be
considered. The guidelines recommend open surgical
repair for chronic dissection in the setting of a con-
nective tissue disorder and a descending thoracic
aortic diameter >5.5 cm. (Class I, Level of Evidence:
B) (4,92). Citing the absence of randomized trial data,
the 2010 ACC/AHA guidelines do not address the
relative efﬁcacy of open versus endovascular repair
for the descending thoracic aorta. The authors note
the FDA approval of stent grafts for aneurysm repair
(TEVAR) on the basis of observational data without
long-term durability data (4).
The Society of Thoracic Surgeons Endovascular
Surgery Task Force consensus document recommends
against endovascular stent grafting in asymptomatic
descending aortic aneurysms <5.5 cm because the
surgical risk of roughly 5% exceeds the risk of aneu-
rysm rupture or dissection (92). Similarly, a 2012 po-
sition statement from the European Association for
Cardio-Thoracic Surgery (EACTS), European Society
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1735of Cardiology (ESC), and European Association of
Percutaneous Cardiovascular Interventions (EAPCI)
recommended endovascular repair in asymptomatic
patients when maximal aneurysm diameter is 5.5 cm
or growth rate exceeds 0.5 cm over 6 months. The
authors acknowledged that this cutoff might be too
conservative for older patients with comorbidities or
not conservative enough in other patients (93). Elef-
teriades (56) suggested that a 6.5 cm cutoff for the
descending aorta may present a more accurate “hinge
point,” after which the risk of complications increases
steeply (56).
Multicenter, prospective, nonrandomized trials
with control groups that included historical controls
evaluated 3 endovascular devices for descending
thoracic aortic aneurysms, all of which had high
successful device placement rates: Gore TAG (W. L.
Gore & Associates, Inc., Flagstaff, Arizona), Medtronic
Talent (Medtronic, Minneapolis, Minnesota), and
Cook Zenith TX2 (Cook Medical, Bloomington, Indi-
ana). The endovascular groups had less morbidity in
all 3 trials, the Gore device had lower aneurysm-
related mortality at 5 years, and the Medtronic
device had lower aneurysm-related and all-cause
mortality at 1 year (94–97).
In the INSTEAD (Investigation Of Stent Grafts in
Patients with type B Aortic Dissection) trial, patients
with chronic (>14 days), uncomplicated type B
dissection were randomized to elective stent-graft
placement with medical therapy (n ¼ 72) or to medi-
cal therapy alone (n ¼ 68). Patients were enrolled
between 2 and 52 weeks after dissection. There was
greater favorable aortic remodeling in the endovas-
cular arm compared to medical therapy, but no dif-
ferences between the groups in all-cause or aortic
mortality at 1 or 2 years (98,99). At 5 years, the TEVAR
group had lower aorta-speciﬁc mortality and less
disease progression, but only using a retrospective
“landmark” analysis (100). IRAD patients who un-
derwent TEVAR for type B dissections had lower
5-year mortality compared to patients treated medi-
cally (15.5% vs. 29.0%; p ¼ 0.018), but these obser-
vational data may reﬂect selection and referral
biases (101).
Despite limited data, the Gore TAG, Medtronic
Talent, and Cook Zenith TX2 stent grafts were
recently FDA-approved for descending thoracic aorta
dissections, and there are at least 4 devices with
new, unique features that are being evaluated in
clinical trials (4,102–104). For patients with acute
uncomplicated type B aortic dissection, 90% survive
with medical therapy aimed mostly at control of
hypertension; therefore, uncomplicated type B
dissections should be treated medically (67,105).The EACTS/ESC/EAPCI 2012 position statement and a
multidisciplinary panel of European experts recom-
mended TEVAR only for complicated type B dissec-
tions. This panel identiﬁed persistent pain,
refractory hypertension, malperfusion, and signs of
rupture, hypotension, or shock as acute complica-
tions. Subacute and chronic complications included:
aortic diameter $5.5 cm; diameter increase >4 mm;
refractory hypertension; recurrent malperfusion; or
recurrent symptoms (106). In recommendations for
acute or chronic type B dissections, the FDA and a
multidisciplinary subcommittee that included the
Society for Vascular Surgery, American Association
for Thoracic Surgery, Society of Thoracic Surgeons,
and the Society for Interventional Radiology, agreed
to limit the deﬁnition of “complicated” dissection
to rupture, impending rupture, or distal malper-
fusion. Using data collected from investigational
device exemption clinical trials between 2000 and
2008, the investigators identiﬁed 99 patients with
complicated type B dissections on the basis of
these criteria. The mortality rate was 10.8% at 30
days and 29.4% at 1 year. At 30 days, rates of stroke,
renal failure, and paralysis were each 9.4%. Based
on these data, the FDA and SVS/AATS/STS/SIR
recommend TEVAR for complicated type B dissec-
tions (79).
4.THORACOABDOMINAL AORTIC ANEURYSM AND
DISSECTION. Thoracoabdominal aneurysms extend
from the descending thoracic aorta into the abdomen
and/or involve the upper abdominal aorta. They are
classiﬁed by Crawford type: type I extend from the
level of the left subclavian artery to the renal arteries;
type II, the most difﬁcult to repair, extend from the
level of the left subclavian artery to the aortoiliac
bifurcation; type III start at or distal to T6 and affect
the lower part of the descending thoracic aorta and
the abdominal aorta; and type IV involve the
abdominal aorta below the diaphragm (107).
Open repair for thoracoabdominal aneurysms, ﬁrst
performed in the late 1950s, was complicated by spi-
nal cord ischemia and paraplegia, and impaired blood
ﬂow to celiac, superior mesenteric, and renal arteries
with subsequent renal failure. Morbidity and mor-
tality have since decreased with improvements in
surgical technique and spinal cord protection, spe-
ciﬁcally hypothermic cardiopulmonary bypass;
monitoring somatosensory-evoked or motor-evoked
potentials to evaluate spinal cord perfusion; cere-
brospinal ﬂuid drainage to increase spinal cord
perfusion pressure; maintaining increased arterial
blood pressure; pressure-controlled perfusion of the
celiac, superior mesenteric, and renal arteries so that
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clamping; and prevention of post-operative hypo-
tension. However, complication rates remain high
(107–111).
Crawford II lesions are only treated with open
surgical repair. For other Crawford lesions, open
surgical repair is the gold standard; hybrid pro-
cedures have been performed in patients at high
surgical risk, as they carry signiﬁcant morbidity and
mortality (107,112–114). The guidelines recommend
surgical repair of thoracoabdominal aneurysms when
diameter >6.0 cm, or less with Marfan syndrome or
other connective tissue disorders (Class I, Level of
Evidence: C). Surgical repair is also recommended
when there is end-organ ischemia or signiﬁcant
celiac, superior mesenteric, or renal artery athero-
sclerosis (Class I, Level of Evidence: B) (4).
CONCLUSIONS
Thoracic aortic aneurysms occur in the setting of
medial degeneration, most commonly due to
increased aortic wall stress from hypertension and,
less commonly, to genetic and inﬂammatory condi-
tions or prior cardiac surgery. The most feared
complication is dissection. On the basis of smallstudies of Marfan patients, medical therapy with
b-blockers and/or ARBs is reasonable to reduce the
rate of aneurysm growth for patients with thoracic
aortic aneurysms. Serial, noninvasive imaging should
be used to follow patients with thoracic aortic an-
eurysms, with referral for surgical repair generally
indicated when the aneurysm reaches a critical
diameter on the basis of location and etiology. In the
future, serological biomarkers may be developed and
validated for diagnosis and prediction of aortic
rupture or dissection. Type A dissection is an emer-
gency, and all patients with this condition should be
assessed for urgent surgery, with which survival
beyond the hospital phase is excellent out to at least
3 years. There is a role for endovascular repair of the
descending thoracic aorta and a potentially expand-
ing role for stent-graft interventions in patients
with thoracic aneurysmal diseases, either as an
alternative to or in conjunction with open surgical
interventions.
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